Loading...
•
Mar 31, 2025
Ultragenyx Q1 2025 Earnings Report
Reported first quarter 2025 financial results and corporate update
Key Takeaways
Ultragenyx reported total revenue of $139 million for the first quarter of 2025, representing 28% growth year-over-year. Net loss improved to $151 million, or $1.57 per share, compared to a net loss of $171 million, or $2.03 per share, in the same period last year. The company reaffirmed its full-year 2025 financial guidance.
Total revenue for Q1 2025 was $139 million, a 28% increase from Q1 2024.
Crysvita revenue in Q1 2025 was $103 million, a 25% increase from Q1 2024.
Net loss for Q1 2025 was $151 million, an improvement from a net loss of $171 million in Q1 2024.
Cash, cash equivalents, and marketable debt securities were $563 million as of March 31, 2025.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Ultragenyx reaffirmed its full-year 2025 financial guidance, expecting total revenue between $640 million and $670 million, Crysvita revenue between $460 million and $480 million, and Dojolvi revenue between $90 million and $100 million. The company anticipates a reduction in 2025 net cash used in operations compared to 2024.
Positive Outlook
- Total revenue expected to grow approximately 14-20% compared to 2024.
- Crysvita revenue guidance of $460 million to $480 million for 2025.
- Dojolvi revenue guidance of $90 million to $100 million for 2025.
- Expected reduction in 2025 net cash used in operations compared to 2024.
- Prioritizing expense management while investing in commercial launches and Phase 3 programs.
Challenges Ahead
- No specific negative guidance points were explicitly stated in the provided text.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...